SNDL Inc.

NASDAQ:SNDL

Drug Manufacturers - Specialty & Generic

Healthcare
$1.34 -1.74%

-$0.03 today

Market cap
$326.64M
Beta
0.91
P/E (TTM)
-47.4
EPS (TTM)
-$0.04
52W Low $1.15High $2.89

Volume 1.00M

Average 2.21M

SNDL Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

SNDL Inc.NASDAQ: SNDL

Cost of Revenue · Q1 FY2026 · quarter ended Mar 2026

Cost of revenue dips below year-ago levels

Q1 FY2026 cost of revenue of CA$143.09M fell 3.5% year over year, behind the +0.2% change in trailing-twelve-month cost of revenue. Sequentially, it fell 21.5% from the prior quarter. Over 3 fiscal years it compounded at +6.3% a year.

Context

  • Cost of revenue amounted to 72.7% of revenue in FY2025, down 1.2 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -3.5% toward the trailing-twelve-month pace of +0.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$143.09M-21.5% QoQ
Last fiscal yearDec 2025
CA$687.75M+1.1% YoY
LTMMar 2026
CA$682.57M+0.2% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.5%——
1 year+1.1%——
3-year CAGR+6.3%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

CAD · from the income statement

Latest · FY2025
687.75M CAD
Year-over-year change
+1.1%
4-year CAGR
+80.3%

Cost of Revenue vs competitors

How SNDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +0.2% is the 6th highest of 8, against a peer median of +15.1%.
  • Cost of revenue amounts to 72.8% of revenue for SNDL, versus a peer median of 34.6%.
SNDL Competitors
Cost of Revenue for SNDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SNDLSNDL Inc.LTM Mar 2026CA$682.57M CAD+0.2%+6.3%72.8%
EBSEmergent BioSolutions Inc.LTM Mar 2026$376M USD-38.7%-15.3%55.6%
ORGOOrganogenesis Holdings Inc.LTM Mar 2026$151.94M USD+37.2%+9.4%29.6%
ESPREsperion Therapeutics, Inc.LTM Mar 2026$146.39M USD+62.5%+68.6%35.0%
EOLSEvolus, Inc.LTM Mar 2026$103.98M USD+17.4%+21.1%34.5%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$44.46M USD-11.9%+20.6%19.1%
SIGASIGA Technologies, Inc.LTM Mar 2026$32.49M USD+15.1%+41.7%34.6%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$18.37M USD+7.2%-4.0%36.5%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$306K USD———
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$55K USD———
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
Peer median (excluding SNDL) —+15.1%+20.6%34.6%

Competitors are the stored peer set for SNDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue56.13M712.2M909.01M920.45M946.4M
Cost of Revenue65.13M571.82M718.59M680.12M687.75M
Gross Profit(9M)140.38M190.42M240.33M258.65M
Gross Margin-16.0%19.7%20.9%26.1%27.3%
Research & Development2.45M2.45M324K346K489K
Selling, General & Admin55.39M158.26M230.17M219.28M210.63M
Operating Expenses125.38M488.15M353.59M344.14M263.07M
Depreciation & Amortization10.16M47.32M64.95M56.71M56.27M
EBITDA(223.76M)(326.55M)(99.15M)(41.2M)48.02M
EBITDA Margin-398.7%-45.9%-10.9%-4.5%5.1%
Operating Income(134.38M)(347.77M)(163.17M)(103.81M)(4.42M)
Operating Margin-239.4%-48.8%-18.0%-11.3%-0.5%
Interest Income13.72M17.62M15.37M16.4M8.05M
Interest Expense776K5.9M7.92M7.7M7.52M
Other Income / Expenses(100.32M)(32M)(8.85M)(1.8M)(11.35M)
Income Before Tax(234.7M)(379.77M)(172.02M)(105.61M)(15.77M)
Pre-Tax Margin-418.1%-53.3%-18.9%-11.5%-1.7%
Income Tax Expense(7.91M)(7.34M)0(9.41M)0
Net Income(226.98M)(335.11M)(172.66M)(94.8M)(15.77M)
Net Margin-404.4%-47.1%-19.0%-10.3%-1.7%
EPS (Basic)(1.24)(1.50)(0.65)(0.38)(0.06)
EPS (Diluted)(1.24)(1.50)(0.65)(0.38)(0.06)
Weighted Avg Shares186.04M229.87M259.37M264.2M258.05M
Weighted Avg Shares (Diluted)186.04M229.87M259.37M264.2M258.05M

SNDL Inc.

NASDAQ:SNDL

Intrinsic Alpha fair value

Locked

Current Price

$1.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.